Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Axiom Research LLC

Neither a doctor nor a teaching hospital

Research payments

$1,984,840

409 payments

Through program year 2025, Axiom Research LLC is reported as receiving $1,984,840 in research payments, across 409 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $881,472 173
2024 Research $300,062 70
2023 Research $165,949 35
2022 Research $245,659 64
2021 Research $172,420 31
2020 Research $81,307 33
2019 Research $137,972 3

Breakdown

Who paid Research payments · program years 2019–2025
  1. AbbVie, Inc. $867,443 179 payments
  2. Biohaven Pharmaceutical Holding Company Ltd. $352,873 78 payments
  3. Pfizer Inc. $200,462 44 payments
  4. Janssen Research & Development, LLC $148,159 28 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $143,044 2 payments
  6. Allergan Inc. $127,090 26 payments
  7. Biohaven Pharmaceuticals, Inc. $86,697 18 payments
  8. Eli Lilly and Company $30,587 8 payments
  9. Eisai Inc. $27,763 25 payments
  10. Amgen Inc. $721 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine $483,167 108 payments
  2. A Phase 4 Randomized Doubleblind Placebocontrolled Study to Evaluate the Efficacy and Safety of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens $227,838 28 payments
  3. PoCC dose finding in Mild to Moderate AD $143,044 2 payments
  4. Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) $136,230 15 payments
  5. A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso $135,019 24 payments
  6. M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine $113,908 24 payments
  7. A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention $108,746 27 payments
  8. A Phase 23 Randomized Doubleblind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention $104,271 40 payments
  9. A Double-Blind, Placebo-Controlled Study of Cariprazine As Adjunctive Therapy in Major Depressive Disorder $86,627 13 payments
  10. A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention $66,745 15 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record